Healthcare professionals are calling for a fundamental shift in public perception around medically supervised weight loss ...

At the intersection of aesthetics and science, RegenCen is changing how patients think about aging. Born from a fusion of ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Kenya’s healthcare system is witnessing a quiet transformation with the introduction of newer therapies for managing Type 2 ...

A new study published by Cleveland Clinic researchers in Diabetes, Obesity and Metabolism investigating the genetic ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide.

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Engineers at Georgia Tech developed a new mode of delivery for injectable medications — an 'exploding' capsule.

Ozempic is a popular drug that, although is meant for diabetic patients, it is more so known for its weight loss side-effect. A small study has found an important aspect of diet for them.

Table of Contents The Real Story Behind Your Changing Body Making Every Bite Count When You’re Eating Less Your Brain […] The ...